[Hexaminolevulinate fluorescence cystoscopy in 2009]

Area of Science:

• Urology
• Oncology
• Medical Imaging

Background:

• Non-muscle-invasive bladder cancer (NMIBC) diagnosis and management remain challenging.
• Standard white light cystoscopy has limitations in detecting all NMIBC, especially carcinoma in situ (CIS).
• Recurrence and understaging are significant concerns in NMIBC management.

Purpose of the Study:

• To evaluate the efficacy of fluorescence cystoscopy in improving NMIBC detection.
• To assess the impact of fluorescence cystoscopy on bladder cancer recurrence rates.
• To highlight the clinical utility and safety of fluorescence cystoscopy.

Main Methods:

• Systematic review and meta-analysis of studies comparing fluorescence cystoscopy with standard cystoscopy.
• Analysis of diagnostic accuracy for NMIBC detection, including CIS.
• Assessment of recurrence rates and side effect profiles.

Main Results:

• Fluorescence cystoscopy significantly improves the detection rate of NMIBC compared to standard cystoscopy.
• The technique is particularly effective in identifying carcinoma in situ (CIS).
• A reduction in tumor recurrence was observed in patients managed with fluorescence cystoscopy.

Conclusions:

• Fluorescence cystoscopy is a valuable tool for enhancing the detection of NMIBC.
• The procedure is well-tolerated with a favorable safety profile.
• Guidelines support its use in specific high-risk bladder cancer cases, including multifocal tumors, large tumors, early recurrence, high-grade cytology, and follow-up of high-risk NMIBC (T1G3 and CIS).